TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07773246: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KRRO-121 in Healthy Volunteers and Pati

Sponsor: Korro Bio, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,002,180

Rescue Site Savings

+$5,954,420

Unlock Full NCT07773246 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07773246 Rescue Dossier →